Were the GYRE share sales made in single trades or multiple transactions?

The GYRE share sales were executed in multiple transactions on each day. Footnotes state the reported price is a weighted average, with individual trades occurring within specific price ranges, and detailed trade-by-trade information is available upon request from the reporting person.

GYRE COO sells shares, exercises stock options

GYRE THERAPEUTICS, INC.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

GYRE THERAPEUTICS, INC. Chief Operating Officer Ye Weiguo reported option exercises and related share sales. He exercised stock options covering 22,220 shares of common stock at an exercise price of $0.75 per share and sold the same number of shares in open-market transactions.

The common stock sales on May 20 and May 21, 2026 were executed at a weighted average price of $6.15 per share, with actual sale prices ranging from about $6.05 to $6.29 according to the footnotes. After these transactions, Ye directly owns 700,000 shares of GYRE common stock.

Insider Trade Summary

Exercise and Sale: 22,220 shares ($120K approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Ye Weiguo

Role Chief Operating Officer

Sold 22,220 shs ($137K)

Approx. gross sale proceeds $137K

Approx. exercise cost $17K

Approx. pre-tax spread $120K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	12,820	$0.00	$0.00
Exercise	Common Stock	12,820	$0.75	$10K
Sale	Common Stock	12,820	$6.15	$79K
Exercise	Stock Option (Right to Buy)	9,400	$0.00	$0.00
Exercise	Common Stock	9,400	$0.75	$7K
Sale	Common Stock	9,400	$6.15	$58K

Holdings After Transaction: Stock Option (Right to Buy) — 904,895 contracts (Direct); Common Stock — 700,000 shares (Direct)

Footnotes (3)

F1. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.0908 to $6.2935. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.05 to $6.22. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3. These options are vested in full.

Key Figures

Shares sold: 22,220 shares Weighted average sale price: $6.15/share Options exercised: 22,220 shares +3 more

6 metrics

Shares sold 22,220 shares Total GYRE common shares sold in open-market transactions

Weighted average sale price $6.15/share Average price for reported GYRE common stock sales

Options exercised 22,220 shares Common shares acquired through stock option exercises

Exercise price $0.75/share Conversion price of stock options into GYRE common stock

Common shares held 700,000 shares Direct GYRE common stock holdings after transactions

Option expiration date October 31, 2030 Expiration of exercised stock options

Key Terms

open-market sale, Stock Option (Right to Buy), weighted average sale price per share, derivative security

4 terms

open-market sale financial

"transaction_action: "open-market sale" for common stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)" in derivative entries"

derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did GYRE COO Ye Weiguo report in this Form 4 filing for GYRE?

Ye Weiguo reported exercising stock options and selling GYRE common shares. He exercised options for 22,220 shares at $0.75 each, then sold 22,220 shares in open-market transactions at a weighted average price of $6.15 per share over two days.

How many GYRE THERAPEUTICS (GYRE) shares did the COO sell and at what price?

He sold a total of 22,220 GYRE common shares in open-market transactions. The weighted average sale price was $6.15 per share, with individual trades executed within price ranges disclosed in the footnotes between approximately $6.05 and $6.29 per share.

What stock options did the GYRE COO exercise according to the Form 4?

He exercised stock options labeled as "Stock Option (Right to Buy)" for 22,220 underlying common shares. These options carried a conversion or exercise price of $0.75 per share and have an expiration date of October 31, 2030, and are described as vested in full.

How many GYRE common shares does the COO hold after the reported transactions?

Following the reported option exercises and related sales, the COO directly holds 700,000 shares of GYRE common stock. This figure reflects his direct ownership after completing both the option exercises and the two days of open-market sale transactions disclosed in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/22/2026 - 06:19 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ye Weiguo

(Last)

(First)

(Middle)

C/O GYRE THERAPEUTICS, INC.

12730 HIGH BLUFF DRIVE, SUITE 250

(Street)

SAN DIEGO

CALIFORNIA

92130

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GYRE THERAPEUTICS, INC. [ GYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/20/2026		M		9,400	A	$0.75	709,400	D
Common Stock	05/20/2026		S		9,400	D	$6.15⁽¹⁾	700,000	D
Common Stock	05/21/2026		M		12,820	A	$0.75	712,820	D
Common Stock	05/21/2026		S		12,820	D	$6.15⁽²⁾	700,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$0.75	05/20/2026		M			9,400	⁽³⁾	10/31/2030	Common Stock	9,400	$0	917,715	D
Stock Option (Right to Buy)	$0.75	05/21/2026		M			12,820	⁽³⁾	10/31/2030	Common Stock	12,820	$0	904,895	D

Explanation of Responses:

1. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.0908 to $6.2935. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.05 to $6.22. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

3. These options are vested in full.

	/s/ Weiguo Ye	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR